Rainbow Coral Corp. (OTCBB: RBCC) is well-positioned to capitalize on
the revolution in medicine being spurred on by 3D printing technology
thanks to the innovative BiO Assay, a new 3D bioprinting system
developed by RBCC's joint venture partner, Nano3D Biosciences (n3D).
Many experts believe that 3D bioprinting equipment like the BiO Assay is
poised to solve the complex problems faced by biotech firms by giving
them the opportunity to test drugs on functional human tissues in order
to better understand and predict a drug's effect on the body. The BiO
Assay uses magnetism to assemble cells in 3D and into conditions that
closely mimic those found in vivo, giving drug makers functional
preclinical human tissues far more useful than any animal or test tube
And with better testing results will come bigger profits for drug
companies, says RBCC CEO Kimberly Palmer.
"Research has been hampered for too long by traditional cell culture
models that have proven to be poor predictors of drug efficacy and
toxicity in humans," Palmer said. "The BiO Assay has been engineered to
reduce costs and improve results across a broad spectrum of tests and
assays. It provides a renewable and easy-to-use source of lifelike cell
cultures that will change the way research is conducted across the
The BiO Assay represents a revolution in pharmaceutical research,
offering better and faster results than have previously been possible.
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and
develop new medical and research technology innovations to compete
alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott
Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow
Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To NFVZone's Homepage ]